Biotech IPO Tracker 2026
Live tracker of biotech and biopharma IPOs in 2026 — therapeutic area, lead asset, stage at IPO, pricing date, offer price, gross proceeds, approximate market cap at listing, and aftermarket performance.
Crossover and pre-IPO rounds are often the first sign of the next listing. Follow them in private biotech financing rounds for 2026.
The tracker refreshes weekly. The daily BioBucks tape flags new filings, launches, pricings, discounts, upsizes, and aftermarket movers every morning.
"Proceeds" reflects gross IPO proceeds before fees and expenses, including confirmed full or partial exercises of underwriters' options disclosed by 14 October 2026. Concurrent private placements are excluded. ADARx includes its option closed on 1 October. Options are not assumed exercised based on share-price performance. Proceeds are attributed to each IPO pricing cohort, not cash received strictly before quarter-end. "MCAP at IPO" is approximate market capitalisation at listing. "vs. offer" is based on share prices as of the 13 November 2026 refresh and will move with the market. Rows are sorted in reverse chronological order by pricing date. For how listing valuations and share counts are calculated, see valuation and fully diluted share terms.
Returns use Yahoo Finance’s 13 November 2026 regular-session closing quotes, excluding after-hours trades. City and Iambic debuted on 16 and 15 October respectively. Their IPO market caps, together with TRexBio and Retension, use final-prospectus post-offering basic share counts multiplied by the offer price, excluding unexercised options and equity awards. Gross IPO proceeds include confirmed exercised underwriters’ options disclosed by 14 October 2026, including ADARx’s option closed on 1 October; concurrent private placements are excluded. Unconfirmed option exercises are not assumed. Lycia is a new addition with US$365.1M proceeds including its confirmed option exercise at the 26 October closing; existing IPO proceeds are otherwise unchanged. Bambusa and Aspen priced on 29 October for US$168.9M and US$140.6M respectively, excluding unexercised options. Their market caps use filed pro forma basic share counts plus confirmed IPO shares at the offer price; Bambusa’s filing includes a liquidity-event RSU settlement assumption. Both debuted on 30 October; their fixed first-day returns use that session’s closing prices, while offer-to-current returns use 13 November closes. All 31 IPOs are marked to the 13 November close. Windward priced on 12 November at US$17 for US$175M gross, excluding the separate US$50M Sanofi placement and unexercised option. It debuted on 13 November at a closing price of US$28.50, a 67.6% gain from offer. Its market cap remains — pending verification.